Making a difference

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in novel science and innovative approaches to bring promising drug candidates to patients, and accelerate their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. We have an in-house team of experts and drug development professionals who follow our companies closely and provide hands-on support.

Droia invests in early financing rounds and also incubates new companies. Operating from Luxembourg and Belgium, Droia invests globally.

Breakthrough focus

For life science companies, ultimate success should be measured in effective patient benefit. Droia invests in companies that develop the most promising and impactful therapies.

Promising therapies will have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed, the improvement in therapeutic benefits as compared to standard of care, and the feasibility of development.

Novel science can innovate in terms of mechanism of action, target, modality, specificity,… Above all, novel therapies should be sufficiently differentiated to earn their place among competing therapies in the future standard of care.

Getting it done

Droia actively participates in the development of the portfolio companies. We aim to support portfolio companies at least up to clinical proof of concept. To this end, Droia’s team has experience in translational science, clinical development and company building. Droia’s team can assist where useful on scientific, preclinical, clinical & CMC development, on IP & regulatory affairs, on licensing, legal, finance & transactions, and on general company building. Droia’s network of life science leaders gives us access to top-level institutions and KOL’s around the world and allows our portfolio companies to benefit from a global knowledge base.


Investment Team

Janwillem Naesens – Partner at DROIA

  • M.Sc. Engineering, University of Leuven
  • McKinsey & Company
  • Waterland Private Equity

* representing Wepaven BV

Janwillem Naesens *

Managing Partner, Oncology & Droia Group

  • Pharm.D., University of Leuven
  • MBA, Vlerick Management School
  • Arthur D. Little
  • TiGenix
  • Prosensa
  • Tusk Therapeutics
  • Independent board member Erytech, Pharvaris

* representing Primix Bio Ventures BV

Luc Dochez *

Managing Partner, Genetic Disease

  • M.Sc. Bio-Engineering, University of Leuven
  • Founder / former owner of Verelst real estate group
  • Seasoned investor in small and big biotech, venture capital
  • Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund

Luc Verelst

Founder & Chairman

  • BA in Biology, University of Virginia
  • PhD in Genetics, University of Wisconsin-Madison
  • Novartis
  • Celgene (Bristol Myers Squibb)
  • Arch Venture Partners
  • Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics, Shattuck Labs and others

George Golumbeski


  • BA in Biochemistry, Catholic University in Chile
  • PhD in Cell Biology, UCSF
  • Medivation
  • Praxis Biotech
  • Merken Biotech

Sebastian Bernales

Venture Partner

  • Msc. Business Engineering, Université Catholique de Louvain
  • Executive Master in Finance, Solvay Business School
  • ING Bank, Corporate Banking
  • Floridienne Group, CFO

* representing Axis Advice SRL

Lionel de Hemptinne *

Chief Financial Officer

  • Master of laws, University of Leuven
  • M.Sc. law and finance, Oxford University and Saïd Business School
  • Cleary Gottlieb Steen & Hamilton
  • Freshfields Bruckhaus Deringer
  • Etex Group

* representing MARA Consulting BV

Matthias De Witte *

General Counsel

  • BSc Pharmacology, McGill University
  • MSc Cancer, University College London
  • PhD Biomedical Sciences, University of Leuven
  • Doctoral research in Angiogenesis and Vascular Metabolism lab, Center for Cancer Biology – VIB
  • FWO PhD Fellowship
  • The UCL Cancer Institute Research Trust and Athena SWAN award for Excellence in Science 2014

Pauline De Zeeuw

Scientific Analyst

  • M. Sc. Biomedical Sciences, University of Leuven
  • PhD Biomedical Sciences – Angiogenesis and Metabolism, University of Leuven
  • Starter Fellowship Emmanuelle van der Schueren, Vlaamse Liga tegen Kanker
  • PhD fellow IWT & Post-doc fellow FWO
  • Nominee Eos Pipet
  • Recipient BiR&D Multidisciplinary PhD Award
  • Scientific publications in e.g. Nature, Cell, Cell Metabolism

Sandra Schoors

Associate Partner

  • Studentship Wellcome Sanger Institute, Cambridge, UK
  • Lab Tech, Center for Medical Genetics, Ghent University, BE
  • PhD Medical Sciences, DNA damage in cancer, University of Cambridge, UK
  • Postdoctoral Fellow, novel drug targets in a rare cancer, New York University Langone Health, USA
  • Recipient Cancer Research UK PhD Fellowship
  • Scientific publications in e.g. JNCI, Oncotarget, Eur J Hum Genet

Elke van Oudenhove

Scientific Analyst

  • M. Sc. Biomedical Sciences, University of Leuven
  • PhD Biomedical Sciences – Tumor Immunology, University of Leuven
  • PhD Pharmaceutical Sciences – Polymers, ULB
  • PhD fellow IWT
  • Recipient VCU RDD Peter R. Byron Graduate Student Award
  • Belgian Brain Tumor Support
  • Scientific publications in e.g. EMBO Mol Med, Oncoimmunology, Journal of Controlled Release

Matthias Van Woensel


  • MSc. Business Engineering, University of Leuven
  • CFA – level I
  • Ernst & Young, M&A advisory
  • Corporate finance, M&A, BD, structuring, tax & legal, modeling & valuation
  • Tusk Therapeutics, interim CFO

Joke Vereecken


  • Professor of Cancer Immunology and Immunotherapy at UCL Cancer Institute
  • Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory
  • CRUK Senior Cancer Research Fellow
  • Co-leading scientist CRUK Cancer Immunotherapy Accelerator
  • CSO at Achilles Therapeutics

Sergio Quezada

IAB Member

  • Executive Chairman of RGenix, Inc
  • Board Member at Biogen, Navidea, Fortress Biotech, Verastem
  • Chief Medical Office/Scientific Advisorr: Hummingbird Biosciences, Oncotartis, Lokon
  • Oncology Advisor, Everest Medicines

Eric Rowinsky

IAB Member

  • Associate Professor in the Department of Biology at the Massachusetts Institute of Technology
  • Associate Director of the Koch Institute for Integrative Cancer Research
  • Institute Member of the Broad Institute of Harvard and MIT
  • Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School

Matthew Vander Heiden

IAB Member

  • Group leader at the Netherlands Cancer Institute
  • Head of the NKI Robotics and Screening Center
  • Expert in large scale functional genomics
  • Pioneer of pooled screening technology
  • Co-founder of Qameleon Therapeutics

Roderick Beijersbergen

IAB Member

  • Professor in the Department of Neurosciences at KU Leuven
  • Group leader at the VIB Center for Brain & Disease Research.
  • Head of the Laboratory of Neurobiology at VIB
  • Scientific Founder of Augustine Therapeutics

Ludo Van Den Bosch

IAB Member


Droia is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment and exit process, and works with the portfolio companies on their progress.

Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.

Droia is an entrepreneurial environment, where everyone is above all committed to making things happen.

Applicants should have relevant experience in biomedical science, drug development and/or life science investing.

Montis Biosciences and Droia Ventures are currently looking for a:
Office Manager / Junior Accountant

Droia SA

27, Boulevard Prince Henri
L-1724 Luxembourg

  Tel. +352 203 01 236

Droia NV

Brusselsesteenweg 11
1860 Meise

  Tel. +32 2 880 67 30